These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Regulation of the antioncogenic Chk2 kinase by the oncogenic Wip1 phosphatase. Fujimoto H, Onishi N, Kato N, Takekawa M, Xu XZ, Kosugi A, Kondo T, Imamura M, Oishi I, Yoda A, Minami Y. Cell Death Differ; 2006 Jul; 13(7):1170-80. PubMed ID: 16311512 [Abstract] [Full Text] [Related]
7. Estrogen receptor alpha binds to peroxisome proliferator-activated receptor response element and negatively interferes with peroxisome proliferator-activated receptor gamma signaling in breast cancer cells. Bonofiglio D, Gabriele S, Aquila S, Catalano S, Gentile M, Middea E, Giordano F, Andò S. Clin Cancer Res; 2005 Sep 01; 11(17):6139-47. PubMed ID: 16144913 [Abstract] [Full Text] [Related]
9. p53-inducible wip1 phosphatase mediates a negative feedback regulation of p38 MAPK-p53 signaling in response to UV radiation. Takekawa M, Adachi M, Nakahata A, Nakayama I, Itoh F, Tsukuda H, Taya Y, Imai K. EMBO J; 2000 Dec 01; 19(23):6517-26. PubMed ID: 11101524 [Abstract] [Full Text] [Related]
10. Regulation of ATM/p53-dependent suppression of myc-induced lymphomas by Wip1 phosphatase. Shreeram S, Hee WK, Demidov ON, Kek C, Yamaguchi H, Fornace AJ, Anderson CW, Appella E, Bulavin DV. J Exp Med; 2006 Dec 25; 203(13):2793-9. PubMed ID: 17158963 [Abstract] [Full Text] [Related]
11. Oncogenic Wip1 phosphatase is inhibited by miR-16 in the DNA damage signaling pathway. Zhang X, Wan G, Mlotshwa S, Vance V, Berger FG, Chen H, Lu X. Cancer Res; 2010 Sep 15; 70(18):7176-86. PubMed ID: 20668064 [Abstract] [Full Text] [Related]
14. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models. Kuske B, Naughton C, Moore K, Macleod KG, Miller WR, Clarke R, Langdon SP, Cameron DA. Endocr Relat Cancer; 2006 Dec 15; 13(4):1121-33. PubMed ID: 17158758 [Abstract] [Full Text] [Related]
15. Wip1 directly dephosphorylates gamma-H2AX and attenuates the DNA damage response. Cha H, Lowe JM, Li H, Lee JS, Belova GI, Bulavin DV, Fornace AJ. Cancer Res; 2010 May 15; 70(10):4112-22. PubMed ID: 20460517 [Abstract] [Full Text] [Related]
16. Wip1 over-expression correlated with TP53/p14(ARF) pathway disruption in human astrocytomas. Wang P, Rao J, Yang H, Zhao H, Yang L. J Surg Oncol; 2011 Nov 01; 104(6):679-84. PubMed ID: 21695702 [Abstract] [Full Text] [Related]
17. Reversal of the ATM/ATR-mediated DNA damage response by the oncogenic phosphatase PPM1D. Lu X, Nguyen TA, Donehower LA. Cell Cycle; 2005 Aug 01; 4(8):1060-4. PubMed ID: 15970689 [Abstract] [Full Text] [Related]
19. PPM1D phosphatase, a target of p53 and RBM38 RNA-binding protein, inhibits p53 mRNA translation via dephosphorylation of RBM38. Zhang M, Xu E, Zhang J, Chen X. Oncogene; 2015 Nov 26; 34(48):5900-11. PubMed ID: 25823026 [Abstract] [Full Text] [Related]
20. The Wip1 Phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop. Lu X, Ma O, Nguyen TA, Jones SN, Oren M, Donehower LA. Cancer Cell; 2007 Oct 26; 12(4):342-54. PubMed ID: 17936559 [Abstract] [Full Text] [Related] Page: [Next] [New Search]